Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where K. De Jaeger is active.

Publication


Featured researches published by K. De Jaeger.


International Journal of Radiation Oncology Biology Physics | 2001

Portal imaging to assess setup errors, tumor motion and tumor shrinkage during conformal radiotherapy for non-small cell lung cancer

Sara Erridge; Yvette Seppenwoolde; C. Goedbloed; Wilma D. Heemsbergen; S.H. Muller; M. van Herk; K. De Jaeger; J. Belderbos; L.J. Boersma; Joos V. Lebesque

PURPOSE To investigate patient set-up, tumor movement and shrinkage during 3D conformal radiotherapy for non-small cell lung cancer. MATERIALS AND METHODS In 97 patients, electronic portal images (EPIs) were acquired and corrected for set-up using an off-line correction protocol based on a shrinking action level. For 25 selected patients, the orthogonal EPIs (taken at random points in the breathing cycle) throughout the 6-7 week course of treatment were assessed to establish the tumor position in each image using both an overlay and a delineation technique. The range of movement in each direction was calculated. The position of the tumor in the digitally reconstructed radiograph (DRR) was compared to the average position of the lesion in the EPIs. In addition, tumor shrinkage was assessed. RESULTS The mean overall set-up errors after correction were 0, 0.6 and 0.2 mm in the x (left-right), y (cranial-caudal) and z (anterior-posterior) directions, respectively. After correction, the standard deviations (SDs) of systematic errors were 1.4, 1.5 and 1.3 mm and the SDs of random errors were 2.9, 3.1 and 2.0 mm in the x-, y- and z-directions, respectively. Without correction, 41% of patients had a set-up error of more than 5 mm vector length, but with the set-up correction protocol this percentage was reduced to 1%. The mean amplitude of tumor motion was 7.3 (SD 2.7), 12.5 (SD 7.3) and 9.4 mm (SD 5.2) in the x-, y- and z-directions, respectively. Tumor motion was greatest in the y-direction and in particular for lower lobe tumors. In 40% of the patients, the projected area of the tumor regressed by more than 20% during treatment in at least one projection. In 16 patients it was possible to define the position of the center of the tumor in the DRR. There was a mean difference of 6 mm vector length between the tumor position in the DRR and the average position in the portal images. CONCLUSIONS The application of the correction protocol resulted in a significant improvement in the set-up accuracy. There was wide variation in the observed tumor motion with more movement of lower lobe lesions. Tumor shrinkage was observed. The position of the tumor on the planning CT scan did not always coincide with the average position as measured during treatment.


Radiotherapy and Oncology | 2013

PD-0097: Impact of new Dutch guideline on patient selection for WBRT in a large lung cancer cohort

Lizza Hendriks; A. Steward; A. van Baardwijk; B. Reymen; S Wanders; G Bootsma; K. De Jaeger; B.E. van den Borne; E.G.C. Troost; A. Dingemans

local control (LC), regional control (RC) and metastasis-free survival (MFS). A strong correlation between total lymph node tumour volume and Nstage was found (Rs=0.93, P<0.01). MFS was worse with involvement of the lower neck levels (Rs=0.345, P<0.01). Patients with larger total lymph node tumour volumes had poorer RC and MFS rates, independent of treatment regimen. For total lymph node volumes up to 3.5 cm, MFS can be improved by ARCON (P<0.01). Conclusions: The strong prognostic value of T-stage and primary tumour volume, observed in retrospective analyses was not confirmed in patients treated in a prospective randomised trial with accelerated radiotherapy with or without carbogen breathing and nicotinamide. Results of this study indicate that (biological) factors other than primary tumour volume and T-stage are needed to select patients with laryngeal cancer for treatment intensification.


International Journal of Radiation Oncology Biology Physics | 2003

In regard to Tsujino et al.: predictive value of dose–volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. IJROBP 2003;55:110–115

Yvette Seppenwoolde; K. De Jaeger; Joos V. Lebesque


International Journal of Radiation Oncology Biology Physics | 2001

Interim analysis of a phase I/II dose escalation trial in non-small cell lung cancer (NSCLC) using three-dimensional conformal radiotherapy (3D-CRT)

J. Belderbos; K. De Jaeger; Wilma D. Heemsbergen; Paul Baas; L.J. Boersma; Joos V. Lebesque


International Journal of Radiation Oncology Biology Physics | 2001

Radiation pneumonitis and NTCP models

Joos V. Lebesque; Yvette Seppenwoolde; J. Belderbos; K. De Jaeger; G.T. Henning; James A. Hayman; Mary K. Martel; R.K. Ten Haken


Lung Cancer | 2000

Dose escalation in NSCLC using three dimensional conformal radiotherapy (3 DCRT)

J. Belderbos; K. De Jaeger; Paul Baas; Joos V. Lebesque


Lung Cancer | 2005

O-145 Prognostic significance of the 18FDG-PET standardized uptake value for inoperable non-small cell lung cancer patients after high-dose radiotherapy

Gerben R. Borst; J. Belderbos; Ronald Boellaard; Emile F.I. Comans; K. De Jaeger; Adriaan A. Lammertsma; Joos V. Lebesque


Journal of Thoracic Oncology | 2015

Determinants of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients

Iris Walraven; M. Ten Berge; R. Damhuis; C. Tissing-Tan; E.G.C. Troost; Bart Reymen; Joachim Widder; F. Koppe; A. Van der Wel; E. Vonk; I. Coremans; J. Bussink; K. De Jaeger; N. Van der Voort Van Zyp; Sherif Y. El Sharouni; H. Knol; D. Woutersen; J. Belderbos


International Journal of Radiation Oncology Biology Physics | 2001

Impact of tumor regression on functional recovery after high-dose radiotherapy in non-small cell lung cancer

K. De Jaeger; Yvette Seppenwoolde; C. Goedbloed; S.H. Muller; Paul Baas; J. Belderbos; L.J. Boersma; Joos V. Lebesque


Radiotherapy and Oncology | 2018

PO-0748: Inter-observer delineation variation and dose to hippocampus in hippocampus avoidance PCI

Fabian Bartel; M. van Herk; Hugo Vrenken; F. Vandaele; Stefan Sunaert; K. De Jaeger; N. J. Dollekamp; C. Carbaat; Emmy Lamers; Edith Dieleman; Yolande Lievens; Dirk De Ruysscher; Sanne B. Schagen; M. De Ruiter; J.C. de Munck; J. Belderbos

Collaboration


Dive into the K. De Jaeger's collaboration.

Top Co-Authors

Avatar

J. Belderbos

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Joos V. Lebesque

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Yvette Seppenwoolde

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

L.J. Boersma

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

M. van Herk

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Paul Baas

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Joachim Widder

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

E.G.C. Troost

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar

Bart Reymen

Maastricht University Medical Centre

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge